Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of QuadraMed Corp. (“QuadraMed” or the “Company”) (Nasdaq:QDHC) related to the proposed acquisition by Francisco Partners, a private equity firm. The deal is valued at approximately $126 million.

Under the terms of the transaction, Francisco Partners will acquire all outstanding shares of QuadraMed common stock for $8.50 per share and the Series A Cumulative Mandatory Convertible Preferred Stock for $13.7097 per share. The investigation concerns, in part, whether the board breached their fiduciary duties by not receiving fair value for the Company. While the parties tout that the offer is a 32.6% premium over the one day share price of the stock, the offer represents only a nominal premium over recent activity. As recently as mid-October 2009, QuadraMed stock traded at over $7.75 per share.

If you are a QuadraMed shareholder and wish to discuss the legal ramifications of the Board’s actions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at clients@brodsky-smith.com, or by calling toll free 877-LEGAL-90.

Grafico Azioni Quadramed Corp (MM) (NASDAQ:QDHC)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Quadramed Corp (MM)
Grafico Azioni Quadramed Corp (MM) (NASDAQ:QDHC)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Quadramed Corp (MM)